Study to IDEntify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS)
Patients treated with crizotinib under routine clinical practice
Patients with a minimum data registered at the medical history
For the patients that will be recruited prospectively: Patients must have a signed informed consent document.
For the ROS1 treatment sub-study (retrospective only):
Age \> 18 years
Confirmation of NSCLC with ROS1-positive translocation
Have been eligible to receive treatment with crizotinib according to routine clinical practice since the market launch of the ROS1 indication in Spain on 8 February 2017 until the opening of the site.
Patients should have a predetermined minimum amount of data recorded in their medical records.
Clareo Health | Study to IDEntify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS)
